Corpus callosum index correlates with brain volumetry and disability in multiple sclerosis patients

References

1. ↵
   1. Brownlee WJ,
   2. Hardy TA,
   3. Fazekas F,
   4. Miller DH

   (2017) Diagnosis of multiple sclerosis: progress and challenges. Lancet 389, 1336–1346.
2. ↵
   1. Dendrou CA,
   2. Fugger L,
   3. Friese MA

   (2015) Immunopathology of multiple sclerosis. Nat Rev Immunol 15, 545–558.
3. ↵
   1. Howard J,
   2. Trevick S,
   3. Younger DS

   (2016) Epidemiology of Multiple Sclerosis. Neurol Clin 34, 919–939.
4. ↵
   1. Garg N,
   2. Reddel SW,
   3. Miller DH,
   4. Chataway J,
   5. Riminton DS,
   6. Barnett Y,
   7. et al.

   (2015) The corpus callosum in the diagnosis of multiple sclerosis and other CNS demyelinating and inflammatory diseases. J Neurol Neurosurg Psychiatry 86, 1374–1382.
5. ↵
   1. Cheong WL,
   2. Mohan D,
   3. Warren N,
   4. Reidpath DD

   (2018) Multiple Sclerosis in the Asia Pacific Region: A Systematic Review of a Neglected Neurological Disease. Front Neurol 9.
6. ↵
   1. Islas MÁM,
   2. Ciampi E

   (2019) Assessment and impact of cognitive impairment in multiple sclerosis: An overview. Biomedicines 7, 1–19.
7. ↵
   1. Sumowski JF,
   2. Benedict R,
   3. Enzinger C,
   4. Filippi M,
   5. Geurts JJ,
   6. Hamalainen P,
   7. et al.

   (2018) Cognition in multiple sclerosis: State of the field and priorities for the future. Neurology 90, 278–288.
8. ↵
   1. Leavitt VM,
   2. Tosto G,
   3. Riley CS

   (2018) Cognitive phenotypes in multiple sclerosis. J Neurol 265, 562–266.
9. ↵
   1. Estiasari R,
   2. Fajrina Y,
   3. Lastri DN,
   4. Melani S,
   5. Maharani K,
   6. Imran D,
   7. et al.

   (2019) Validity and Reliability of Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS) in Indonesia and the Correlation with Quality of Life. Neurol Res Int 2019, 1–7.
10. ↵
    1. Ghione E,
    2. Bergsland N,
    3. Dwyer MG,
    4. Hagemeier J,
    5. Jakimovski D,
    6. Paunkoski I,
    7. et al.

    (2018) Brain Atrophy Is Associated with Disability Progression in Patients with MS followed in a Clinical Routine. Am J Neuroradiol 39, 2237–2242.
11. ↵
    1. Lassmann H

    (2018) Multiple sclerosis pathology. Cold Spring Harb Perspect Med 8, 1–16.
12. ↵
    1. Popescu V,
    2. Klaver R,
    3. Voorn P,
    4. Galis-De Graaf Y,
    5. Knol DL,
    6. Twisk JWR,
    7. et al.

    (2015) What drives MRI-measured cortical atrophy in multiple sclerosis? Mult Scler 21, 1280–1290.
13. ↵
    1. Rojas JI,
    2. Patrucco L,
    3. Miguez J,
    4. Cristiano E

    (2016) Brain atrophy in multiple sclerosis: therapeutic, cognitive and clinical impact. Arq Neuropsiquiatr 74, 235–243.
14. ↵
    1. Grothe M,
    2. Lotze M,
    3. Langner S,
    4. Dressel A

    (2016) The role of global and regional gray matter volume decrease in multiple sclerosis. J Neurol 263, 1137–1145.
15. 1. Bergsland N,
    2. Horakova D,
    3. Dwyer MG,
    4. Uher T,
    5. Vaneckova M,
    6. Tyblova M,
    7. et al.

    (2018) Gray matter atrophy patterns in multiple sclerosis: A 10-year source-based morphometry study. NeuroImage Clin 17, 444–451.
16. ↵
    1. Fisher E,
    2. Lee JC,
    3. Nakamura K,
    4. Rudick RA

    (2008) Gray matter atrophy in multiple sclerosis: A longitudinal study. Ann Neurol 64, 255–265.
17. ↵
    1. Alroughani R,
    2. Deleu D,
    3. El Salem K,
    4. Al-Hashel J,
    5. Alexander KJ,
    6. Abdelrazek MA,
    7. et al.

    (2016) A regional consensus recommendation on brain atrophy as an outcome measure in multiple sclerosis. BMC Neurol 16, 240.
18. ↵
    1. Paul F

    1. Llufriu S,
    2. Blanco Y,
    3. Martinez-Heras E,
    4. Casanova-Molla J,
    5. Gabilondo I,
    6. Sepulveda M,
    7. et al.

    (2012) Influence of Corpus Callosum Damage on Cognition and Physical Disability in Multiple Sclerosis: A Multimodal Study. in PLoS One, ed Paul F 7, e37167.
19. ↵
    1. Granberg T,
    2. Martola J,
    3. Bergendal G,
    4. Shams S,
    5. Damangir S,
    6. Aspelin P,
    7. et al.

    (2015) Corpus callosum atrophy is strongly associated with cognitive impairment in multiple sclerosis: Results of a 17-year longitudinal study. Mult Scler J 21, 1151–1158.
20. ↵
    1. Papathanasiou A,
    2. Messinis L,
    3. Zampakis P,
    4. Papathanasopoulos P

    (2017) Corpus callosum atrophy as a marker of clinically meaningful cognitive decline in secondary progressive multiple sclerosis. Impact on employment status. J Clin Neurosci 43, 170–175.
21. ↵
    1. Dewey J,
    2. Hana G,
    3. Russell T,
    4. Price J,
    5. McCaffrey D,
    6. Harezlak J,
    7. et al.

    (2010) Reliability and validity of MRI-based automated volumetry software relative to auto-assisted manual measurement of subcortical structures in HIV-infected patients from a multisite study. Neuroimage 51, 1334–1344.
22. ↵
    1. Vidal-Jordana A,
    2. Pareto D,
    3. Sastre-Garriga J,
    4. Auger C,
    5. Ciampi E,
    6. Montalban X,
    7. et al.

    (2017) Measurement of Cortical Thickness and Volume of Subcortical Structures in Multiple Sclerosis: Agreement between 2D Spin-Echo and 3D MPRAGE T1-Weighted Images. Am J Neuroradiol 38, 250–256.
23. ↵
    1. Figueira FFA,
    2. dos Santos VS,
    3. Figueira GMA,
    4. da Silva ÂCM

    (2007) Corpus Callosum Index: A practical method for long-term follow-up in multiple sclerosis. Arq Neuropsiquiatr 65, 931–935.
24. ↵
    1. Yaldizli Ö,
    2. Atefy R,
    3. Gass A,
    4. Sturm D,
    5. Glassl S,
    6. Tettenborn B,
    7. et al.

    (2010) Corpus callosum index and long-term disability in multiple sclerosis patients. J Neurol 257, 1256–1264.
25. ↵
    1. Fischl B

    (2012) FreeSurfer. Neuroimage 62, 774–781.
26. ↵
    1. Gonçalves LI,
    2. dos Passos GR,
    3. Conzatti LP,
    4. Burger JLP,
    5. Tomasi GH,
    6. Zandoná MÉ,
    7. et al.

    (2018) Correlation between the corpus callosum index and brain atrophy, lesion load, and cognitive dysfunction in multiple sclerosis. Mult Scler Relat Disord 20, 154–158.
27. ↵
    1. Evangelou N

    (2000) Regional axonal loss in the corpus callosum correlates with cerebral white matter lesion volume and distribution in multiple sclerosis. Brain 123, 1845–1849.
28. ↵
    1. Radü E,
    2. Bendfeldt K,
    3. Mueller-Lenke N,
    4. Magon S,
    5. Sprenger T

    (2013) Brain atrophy: an in-vivo measure of disease activity in multiple sclerosis. Swiss Med Wkly 143, 1–11.
29. ↵
    1. Eshaghi A,
    2. Prados F,
    3. Brownlee WJ,
    4. Altmann DR,
    5. Tur C,
    6. Cardoso MJ,
    7. et al.

    (2018) Deep gray matter volume loss drives disability worsening in multiple sclerosis. Ann Neurol 83, 210–222.
30. ↵
    1. Pukenas B

    (2011) Normal Brain Anatomy on Magnetic Resonance Imaging. Magn Reson Imaging Clin N Am 19, 429–437.
31. ↵
    1. Bergsland N

    1. Koskimäki F,
    2. Bernard J,
    3. Yong J,
    4. Arndt N,
    5. Carroll T,
    6. Lee SK,
    7. et al.

    (2018) Gray matter atrophy in multiple sclerosis despite clinical and lesion stability during natalizumab treatment. in PLoS One, ed Bergsland N 13, e0209326.
32. ↵
    1. Jehna M,
    2. Pirpamer L,
    3. Khalil M,
    4. Fuchs S,
    5. Ropele S,
    6. Langkammer C,
    7. et al.

    (2015) Periventricular lesions correlate with cortical thinning in multiple sclerosis. Ann Neurol 78, 530–539.
33. ↵
    1. Yaldizli Ö,
    2. Penner IK,
    3. Frontzek K,
    4. Naegelin Y,
    5. Amann M,
    6. Papadopoulou A,
    7. et al.

    (2014) The relationship between total and regional corpus callosum atrophy, cognitive impairment and fatigue in multiple sclerosis patients. Mult Scler J 20, 356–364.
34. ↵
    1. Caligiuri ME,
    2. Barone S,
    3. Cherubini A,
    4. Augimeri A,
    5. Chiriaco C,
    6. Trotta M,
    7. et al.

    (2015) The relationship between regional microstructural abnormalities of the corpus callosum and physical and cognitive disability in relapsing-remitting multiple sclerosis. NeuroImage Clin 7, 28–33.
35. ↵
    1. Barone S,
    2. Caligiuri ME,
    3. Valentino P,
    4. Cherubini A,
    5. Chiriaco C,
    6. Granata A,
    7. et al.

    (2018) Multimodal assessment of normal-appearing corpus callosum is a useful marker of disability in relapsing-remitting multiple sclerosis: an MRI cluster analysis study. J Neurol 265, 2243–2250.
36. ↵
    1. Vaneckova M,
    2. Kalincik T,
    3. Krasensky J,
    4. Horakova D,
    5. Havrdova E,
    6. Hrebikova T,
    7. et al.

    (2012) Corpus Callosum Atrophy– A Simple Predictor of Multiple Sclerosis Progression: A Longitudinal 9-Year Study. Eur Neurol 68, 23–27.